Search ARM

Q3 2018 Data Report


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

892+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total Q3 2018 Global Financings

Total Global Financing

$2.8 Billion

 59%

Increase from Q3 2017

 40%

Increase year-over-year
$10.7B Raised YTD 2018

Gene & Gene-modified
Cell Therapy

$2.1 Billion

 35%

Increase from Q3 2017

 34%

Increase year-over-year
$7.8B raised YTD 2018

Cell Therapy

$1.8 Billion

 73%

Increase from Q3 2017

 32%

Increase year-over-year
$6.0B raised YTD 2018

Tissue Engineering

$1.5 Million

 91%

Decrease from Q3 2017

213%

Increase year-over-year
$786M raised YTD 2018

Total Global Financings by Type, by Year

1003

Clinical trials underway
worldwide by the end of Q3 2018

PH. 1

330

PH. 2

580

PH. 3

93

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q3 2018

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q3 2018

Report Infographics